Search hospitals > Florida > Saint Petersburg
Meridien Research
Claim this profileSaint Petersburg, Florida 33709
Global Leader in Alzheimer's Disease
Conducts research for Depression
Conducts research for Major Depression
Conducts research for Depression Treatment
Conducts research for Diabetes
115 reported clinical trials
1 medical researcher
Summary
Meridien Research is a medical facility located in Saint Petersburg, Florida. This center is recognized for care of Alzheimer's Disease, Depression, Major Depression, Depression Treatment, Diabetes and other specialties. Meridien Research is involved with conducting 115 clinical trials across 122 conditions. There are 1 research doctors associated with this hospital, such as Jay Meyer.Top PIs
Clinical Trials running at Meridien Research
COVID-19
Coronavirus
Coronavirus Infection
Post-COVID Syndrome
Epstein-Barr Virus Infection
EBV Infection
mRNA-1273.214 Vaccine
for COVID-19 in Children
This trial tests updated COVID-19 vaccines on young children. The vaccines use mRNA to teach the body to recognize and fight the virus. The study aims to ensure these vaccines are safe and effective for this age group.
Recruiting3 awards Phase 3
COVID-19 Vaccine
for Children
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. * Substudy A design: Phase 1 includes participants 6 months through less than 4 years 3 months of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naïve) and will receive 3 doses of study vaccine as their initial series, followed by a fourth dose of study vaccine. Phase 2/3 includes participants 6 months through less than 5 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive 1, 2, or 3 doses of study vaccine, depending on what group they are in. * Substudy B design: includes participants 6 months through less than 5 years of age who have either received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. * Substudy C design: Phase 1 includes participants 6 months through less than 5 years of age who have received 3 prior doses of BNT162b2 and will receive study vaccine as their fourth dose. * Substudy D design: includes participants 5 through less than12 years of age who have received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. * Substudy E design: includes participants 2 through less than 12 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive a single dose of study vaccine.
Recruiting1 award Phase 2 & 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Meridien Research?
Meridien Research is a medical facility located in Saint Petersburg, Florida. This center is recognized for care of Alzheimer's Disease, Depression, Major Depression, Depression Treatment, Diabetes and other specialties. Meridien Research is involved with conducting 115 clinical trials across 122 conditions. There are 1 research doctors associated with this hospital, such as Jay Meyer.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.